ABCL

AbCellera Biologics Inc. 8-K Summary

Business Context and Reporting Period

This Form 8-K reports on the Annual Meeting of Shareholders held by AbCellera Biologics Inc. on June 13, 2024. The record date for the meeting was April 15, 2024, with 293,921,356 common shares outstanding and entitled to vote.

Key Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and shareholder voting results.

Material Changes and Voting Results

Shareholders voted on three proposals, all of which were approved:

• Proposal 1 (Director Election): Véronique Lecault, Ph.D., and Andrew Lo, Ph.D., were elected as Class I directors for a three-year term.
• Proposal 2 (Auditor Ratification): KPMG LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
• Proposal 3 (Say-on-Pay): Shareholders approved the compensation of named executive officers on a non-binding advisory basis.

Voting Breakdown

Broker non-votes totaled 23,405,619 common shares for both Proposal 1 and Proposal 3.

Guidance, Outlook, and Risks

The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.

Key Facts for Investors to Verify

• Confirmation of the new board composition following the election of Dr. Lecault and Dr. Lo.
• The level of shareholder support for executive compensation (Say-on-Pay), noting the 7.4 million votes cast against.
• The significant number of abstentions for Andrew Lo, Ph.D. (30.3 million votes) compared to Véronique Lecault, Ph.D. (15.1 million votes).
• Verification of the total outstanding share count (293,921,356) against the sum of votes cast and broker non-votes.